Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy

Neurology

Volumn 60, Issue 8, 2003, Pages 1388-1390

  Marra, C M ^a,c   Lockhart, D ^b   Zunt, J R ^a   Perrin, M ^a   Coombs, R W ^a   Collier, A C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COLONY STIMULATING FACTOR; INDINAVIR; PROTEIN INHIBITOR; RNA; ZIDOVUDINE;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPSYCHOLOGY; PRIORITY JOURNAL; TASK PERFORMANCE;

EID: 0346187002     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000058768.73358.1A     Document Type: Article

References (6)

1. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-390.
2. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
3. Zhong L, Yeh KC. Determination of indinavir in human cerebrospinal fluid and plasma by solid-phase extraction and high-performance liquid chromatography with column switching. J Chromatogr B Biomed Sci Appl 1999;734:63-71.
4. Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998;51:221-228.
5. White H. Maximum likelihood estimation of misspecified models. Econometrica 1982;50:1-26.
6. Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999;13:1051-1061.